Literature DB >> 19036492

Hysteroscopic myomectomy for menorrhagia using Versascope bipolar system: efficacy and prognostic factors at a minimum of one year follow up.

Rajesh Varma1, Hemi Soneja, T Justin Clark, Janesh K Gupta.   

Abstract

OBJECTIVE: To evaluate the effectiveness of hysteroscopic submucous myomectomy for women with heavy menstrual bleeding (HMB) over a minimum 1-year period and assess prognostic factors associated with treatment success. STUDY
DESIGN: Prospective observational study set in a university teaching hospital in UK involving 92 women symptomatic of HMB with submucous myomas consecutively recruited between June 2003 and November 2006. Hysteroscopic myomectomy was performed under outpatient local anaesthetic (n=35, 38%) or daycase general anaesthesia (n=57, 62%) using Gynecare Versascope bipolar system. The main outcome measures were: the need for secondary surgical or medical re-intervention, menstrual improvement and patient satisfaction. Other outcome measures include: successful completion of primary resection, type of secondary treatment. RESULT: Mean follow up was 2.6 years (95% CI 2.3-2.9). Complete fibroid excision was achieved in 66%. Secondary surgical re-intervention was required in 27 (29%) of which 11 (12%) were repeat hysteroscopic myomectomy and 10 (11%) were hysterectomy procedures. Multiple uterine fibroids and adenomyosis were identified in 80% of hysterectomies. At follow up, improved menstrual symptoms and patient satisfaction were reported by 91% and 86%, respectively. Irregular cycle HMB and incomplete fibroid excision were associated with secondary retreatment. Size of the submucous fibroid resected, presence of intramural and subserosal fibroids, or LA vs. GA setting were unrelated to treatment success.
CONCLUSION: HMB with submucous myomas may be successfully treated by completely removing the intracavity myoma component, irrespective of co-existent intramural or subserosal fibroids or size of fibroid resected. This effect remains sustained over at least a 1-2 year period.

Entities:  

Mesh:

Year:  2008        PMID: 19036492     DOI: 10.1016/j.ejogrb.2008.10.006

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  5 in total

Review 1.  A Systematic Review of Minimally Invasive Treatments for Uterine Fibroid-Related Bleeding.

Authors:  Jiahui Zhang; Virginia-Arlene Go; Jaime Friel Blanck; Bhuchitra Singh
Journal:  Reprod Sci       Date:  2021-09-03       Impact factor: 2.924

2.  Sonohysterographic predictors of successful hysteroscopic myomectomies.

Authors:  Martin D Keltz; Alexis D Greene; Mary Breda Morrissey; Mario Vega; Erin Moshier
Journal:  JSLS       Date:  2015 Jan-Mar       Impact factor: 2.172

3.  The (cost) effectiveness of procedural sedation and analgesia versus general anaesthesia for hysteroscopic myomectomy, a multicentre randomised controlled trial: PROSECCO trial, a study protocol.

Authors:  Julia F van der Meulen; Marlies Y Bongers; Sjors F P J Coppus; Judith E Bosmans; José M C Maessen; Katrien Oude Rengerink; Lucilla E Overdijk; Celine M Radder; Lucet F van der Voet; Nicol A C Smeets; Huib A A M van Vliet; Wouter J K Hehenkamp; Arentje P Manger; Wilbert A Spaans; Erica A Bakkum; Nicole Horrée; Justine M Briët; Jan Willem van der Steeg; Helen S Kok
Journal:  BMC Womens Health       Date:  2019-03-22       Impact factor: 2.809

4.  Hysteroscopic myomectomy without anesthesia.

Authors:  Nuria-Laia Rodríguez-Mias; Montserrat Cubo-Abert; Laura Gomila-Villalonga; Juanjo Gómez-Cabeza; Jose Luis Poza-Barrasús; Antonio Gil-Moreno
Journal:  Obstet Gynecol Sci       Date:  2019-04-04

Review 5.  The prevalence of occult leiomyosarcoma at surgery for presumed uterine fibroids: a meta-analysis.

Authors:  Elizabeth A Pritts; David J Vanness; Jonathan S Berek; William Parker; Ronald Feinberg; Jacqueline Feinberg; David L Olive
Journal:  Gynecol Surg       Date:  2015-05-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.